Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment

BackgroundAbout 15 years ago, a diverse group of new recreational psychotropic substances began to emerge, which were marketed for example as “legal highs,” “research chemicals,” or “designer drugs.” These substances were later subsumed under the label “Novel Psychoactive Substances” (NPS). Importan...

Full description

Bibliographic Details
Main Authors: Michael Specka, Thomas Kuhlmann, Jürgen Sawazki, Udo Bonnet, Renate Steinert, Monika Cybulska-Rycicki, Helmut Eich, Benita Zeiske, Antje Niedersteberg, Luzia Schaaf, Norbert Scherbaum
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-07-01
Series:Frontiers in Psychiatry
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fpsyt.2020.00569/full
_version_ 1818321844274462720
author Michael Specka
Thomas Kuhlmann
Jürgen Sawazki
Udo Bonnet
Renate Steinert
Monika Cybulska-Rycicki
Helmut Eich
Benita Zeiske
Antje Niedersteberg
Luzia Schaaf
Norbert Scherbaum
author_facet Michael Specka
Thomas Kuhlmann
Jürgen Sawazki
Udo Bonnet
Renate Steinert
Monika Cybulska-Rycicki
Helmut Eich
Benita Zeiske
Antje Niedersteberg
Luzia Schaaf
Norbert Scherbaum
author_sort Michael Specka
collection DOAJ
description BackgroundAbout 15 years ago, a diverse group of new recreational psychotropic substances began to emerge, which were marketed for example as “legal highs,” “research chemicals,” or “designer drugs.” These substances were later subsumed under the label “Novel Psychoactive Substances” (NPS). Important NPS classes are cathinones, synthetic cannabimimetics, phenethylamines, and herbal drugs. The health care system for psychotropic substance use disorders (SUDs) traditionally focused on a few substances, such as alcohol, heroin, cocaine, amphetamines, or cannabis. Users of illicit substances often engage in polydrug use. However little is known about the prevalence of NPS use within the group of “classical” illicit substance users.ObjectiveWe investigated lifetime and recent use of NPS and other drugs in patients who underwent in-patient detoxification treatment from illicit drugs in Germany.MethodsIn a multicenter study with eight participating facilities, patients admitted to treatment underwent a standardized interview at admission, concerning their past and current substance use. The interview comprised classical substances of abuse, NPS, and rarely used substances such as LSD. In addition, participating sites had the opportunity to analyze their patients’ routine drug screenings by means of gas chromatography/mass spectrometry (GC/MS), which permitted detection of NPS.ResultsInterviews from 295 patients could be analyzed. Most patients were opiate dependent and multiple substance users. About 32% reported use of synthetic cannabimimetics during lifetime, but usually only a few times. An important reason for their use was that NPS were not detected by drug testing in prisons or drug treatment facilities. Cathinones, herbal drugs or other NPS had rarely been used during lifetime. NPS use during the last 30 days before admission was nearly zero. This was confirmed by urine analysis results. In contrast, lifetime and current use of opiates, alcohol, cocaine, benzodiazepines, and cannabis was high. In addition, 18% reported of regular unprescribed pregabalin use during lifetime, and 20% had recently used pregabalin.ConclusionPatients admitted to drug detoxification treatment showed multiple substance use, but this did not include NPS use. The diversion of legal medications such as pregabalin in this group is a serious concern.
first_indexed 2024-12-13T10:47:21Z
format Article
id doaj.art-6cc575750f8249c78f908a0c38ebe531
institution Directory Open Access Journal
issn 1664-0640
language English
last_indexed 2024-12-13T10:47:21Z
publishDate 2020-07-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Psychiatry
spelling doaj.art-6cc575750f8249c78f908a0c38ebe5312022-12-21T23:50:04ZengFrontiers Media S.A.Frontiers in Psychiatry1664-06402020-07-011110.3389/fpsyt.2020.00569549087Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification TreatmentMichael Specka0Thomas Kuhlmann1Jürgen Sawazki2Udo Bonnet3Renate Steinert4Monika Cybulska-Rycicki5Helmut Eich6Benita Zeiske7Antje Niedersteberg8Luzia Schaaf9Norbert Scherbaum10LVR Hospital Essen Department of Addictive Behaviour and Addiction Medicine, Medical Faculty, University of Duisburg-Essen, Essen, GermanyPsychosomatische Klinik Bergisch Gladbach, Bergisch Gladbach, GermanyLVR Clinic Viersen, Viersen, GermanyCastrop-Rauxel Evangelical Hospital, Castrop-Rauxel, GermanyLWL-Klinik Münster, Münster, North Rhine-Westphalia, GermanyLVR Clinic Langenfeld, Langenfeld, GermanyClinic Maria Hilf GmbH, Moenchengladbach, GermanyAlexius/Josef Hospital, Neuss, GermanyLVR Clinic Düren, Düren, GermanyLVR Clinic Viersen, Viersen, GermanyLVR Hospital Essen Department of Addictive Behaviour and Addiction Medicine, Medical Faculty, University of Duisburg-Essen, Essen, GermanyBackgroundAbout 15 years ago, a diverse group of new recreational psychotropic substances began to emerge, which were marketed for example as “legal highs,” “research chemicals,” or “designer drugs.” These substances were later subsumed under the label “Novel Psychoactive Substances” (NPS). Important NPS classes are cathinones, synthetic cannabimimetics, phenethylamines, and herbal drugs. The health care system for psychotropic substance use disorders (SUDs) traditionally focused on a few substances, such as alcohol, heroin, cocaine, amphetamines, or cannabis. Users of illicit substances often engage in polydrug use. However little is known about the prevalence of NPS use within the group of “classical” illicit substance users.ObjectiveWe investigated lifetime and recent use of NPS and other drugs in patients who underwent in-patient detoxification treatment from illicit drugs in Germany.MethodsIn a multicenter study with eight participating facilities, patients admitted to treatment underwent a standardized interview at admission, concerning their past and current substance use. The interview comprised classical substances of abuse, NPS, and rarely used substances such as LSD. In addition, participating sites had the opportunity to analyze their patients’ routine drug screenings by means of gas chromatography/mass spectrometry (GC/MS), which permitted detection of NPS.ResultsInterviews from 295 patients could be analyzed. Most patients were opiate dependent and multiple substance users. About 32% reported use of synthetic cannabimimetics during lifetime, but usually only a few times. An important reason for their use was that NPS were not detected by drug testing in prisons or drug treatment facilities. Cathinones, herbal drugs or other NPS had rarely been used during lifetime. NPS use during the last 30 days before admission was nearly zero. This was confirmed by urine analysis results. In contrast, lifetime and current use of opiates, alcohol, cocaine, benzodiazepines, and cannabis was high. In addition, 18% reported of regular unprescribed pregabalin use during lifetime, and 20% had recently used pregabalin.ConclusionPatients admitted to drug detoxification treatment showed multiple substance use, but this did not include NPS use. The diversion of legal medications such as pregabalin in this group is a serious concern.https://www.frontiersin.org/article/10.3389/fpsyt.2020.00569/fullnovel psychoactive substancespregabalin abusemultiple substance usedrug dependencedrug detoxificationopiate dependents
spellingShingle Michael Specka
Thomas Kuhlmann
Jürgen Sawazki
Udo Bonnet
Renate Steinert
Monika Cybulska-Rycicki
Helmut Eich
Benita Zeiske
Antje Niedersteberg
Luzia Schaaf
Norbert Scherbaum
Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
Frontiers in Psychiatry
novel psychoactive substances
pregabalin abuse
multiple substance use
drug dependence
drug detoxification
opiate dependents
title Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
title_full Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
title_fullStr Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
title_full_unstemmed Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
title_short Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment
title_sort prevalence of novel psychoactive substance nps use in patients admitted to drug detoxification treatment
topic novel psychoactive substances
pregabalin abuse
multiple substance use
drug dependence
drug detoxification
opiate dependents
url https://www.frontiersin.org/article/10.3389/fpsyt.2020.00569/full
work_keys_str_mv AT michaelspecka prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT thomaskuhlmann prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT jurgensawazki prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT udobonnet prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT renatesteinert prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT monikacybulskarycicki prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT helmuteich prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT benitazeiske prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT antjeniedersteberg prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT luziaschaaf prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment
AT norbertscherbaum prevalenceofnovelpsychoactivesubstancenpsuseinpatientsadmittedtodrugdetoxificationtreatment